Anti-Mullerian hormone predicts menopause in women with HIV

(HealthDay)—For HIV-infected women, anti-müllerian hormone is associated with age of menopause onset, according to a study published in the January issue of the American Journal of Obstetrics & Gynecology.

Rebecca Scherzer, Ph.D., from the University of California, San Francisco, and colleagues examined the correlation between anti-müllerian hormone and age of menopause onset in 2,461 HIV-infected women. The authors identified factors associated with age at final menstrual period in multivariable normal mixture models for censored data.

The researchers found that even after multivariable adjustment for smoking, CD4 cell count, plasma HIV RNA, hepatitis C infection, and history of clinical AIDS, higher anti-müllerian hormone at age 40 years correlated with later age at final menstrual period. There was a 1.5-year increase in the age at final menstrual period for each doubling of anti-müllerian hormone. The median age at final menstrual period varied from 45 to 52 years for those in the 10th and 90th percentiles of anti-müllerian hormone, respectively. There were independent associations for smoking, hepatitis C infection, higher HIV RNA levels, and history of clinical AIDS with earlier age at final menstrual period.

"Measuring anti-müllerian hormone in HIV-infected women may enable clinicians to predict risk of early menopause, and potentially implement individualized treatment plans to prevent menopause-related comorbidities and to aid in interpretation of symptoms," the authors write.

Two authors disclosed financial ties to the pharmaceutical and medical device industries.